Silencing Nociceptor Neurons Reduces Allergic Airway Inflammation

Publication information:

Sébastien Talbot, Raja-Elie Abdulnour, Patrick Burkett, Seungkyu Lee, Shane Cronin, Maud Pascal, Cedric Laedermann, Simmie Foster, Johnathan Tran, Nicole Lai, Isaac Chiu, Nader Ghasemlou, Matthew DiBiase, David Roberson, Christian Von Hehn, Busranour Agac, Oliver Haworth, Hiroyuki Seki, Josef Penninger, Vijay Kuchroo, Bruce Bean, Bruce Levy, and Clifford Woolf. 2015. “Silencing Nociceptor Neurons Reduces Allergic Airway Inflammation”. Neuron, 87, 2, Pp. 341-54. doi:10.1016/j.neuron.2015.06.007

Abstract

Lung nociceptors initiate cough and bronchoconstriction. To elucidate if these fibers also contribute to allergic airway inflammation, we stimulated lung nociceptors with capsaicin and observed increased neuropeptide release and immune cell infiltration. In contrast, ablating Nav1.8(+) sensory neurons or silencing them with QX-314, a charged sodium channel inhibitor that enters via large-pore ion channels to specifically block nociceptors, substantially reduced ovalbumin- or house-dust-mite-induced airway inflammation and bronchial hyperresponsiveness. We also discovered that IL-5, a cytokine produced by activated immune cells, acts directly on nociceptors to induce the release of vasoactive intestinal peptide (VIP). VIP then stimulates CD4(+) and resident innate lymphoid type 2 cells, creating an inflammatory signaling loop that promotes allergic inflammation. Our results indicate that nociceptors amplify pathological adaptive immune responses and that silencing these neurons with QX-314 interrupts this neuro-immune interplay, revealing a potential new therapeutic strategy for asthma.